The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS).
This article was originally published on MedicalXpress.com
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
© 2024 SimplyWell.ca